GDGargi Damle

Gargi Damle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gargi Damle has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures from Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer

    by Rahat Alam, Anna Reva, David G. Edwards, Bree M. Lege, Laura S. Munoz-Arcos, Carolina Reduzzi, Swarnima Singh, Xiaoxin Hao, Yi-Hsuan Wu, Zeru Tian, et al.

    Supplementary Figure 1 Shows the distribution of ERBB2 mutations among metastatic cancer patients, survival outcomes according to metastatic sites (bone vs visceral), and detailed CTC counts from HR+/Her2- MBC patients. Supplementary Figure 2 Shows the therapeutic effect of Tras-ALN on metastasis spread from bone metastasis models of HR+ breast cancer via uCT, live and ex vivo bioluminescence profiling of metastatic organs. Supplementary Figure 3 shows the increased expression of ERBB2 in MSC 3D coculture and anti-ER treatment conditions. Supplementary Figure 4 shows the immune-independent effect of Tras-ALN in blocking metastasis progression. Supplementary Figure 5 shows that direct cell-cell interaction is not required for MSC-induced Her2 expression based on 3D transwell culture conditions. Supplementary 1 of Figure 6 shows genetic modulations of Her2 (ERBB2) in MCF7 and ZR75-1 breast cancer models. Supplementary 2 of Figure 6 shows that genetic alteration of Her2 impacts multiorgan metastasis seeding in HR+ breast cancer models. Supplementary 1 of Figure 7 shows that miRNAs with Her2 targeting potential are associated with overall survival in breast cancer. Supplementary 2 of Figure 7 shows that miR-133a/b abrogates brain metastasis seeding from bone-derived ZR75-1 cells.

  • Open Access

    Data from Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer

    by Rahat Alam, Anna Reva, David G. Edwards, Bree M. Lege, Laura S. Munoz-Arcos, Carolina Reduzzi, Swarnima Singh, Xiaoxin Hao, Yi-Hsuan Wu, Zeru Tian, et al.

    Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort of 137 patients with metastatic breast cancer with initial HR+/HER2− status and use preclinical models of bone metastasis (BM) to validate the role of HER2E CTCs in multiorgan metastases. Although HER2 expression was higher in patients with BM, experimental analyses revealed that HER2E CTCs derived from bone lesions were more dependent on HER2 activity and more susceptible to anti-HER2 therapy. Targeting the bone-mediated HER2 induction reduces CTC detection and abrogates secondary metastasis from the bone. Overall, we elucidate that HER2E CTCs can serve as a noninvasive biomarker for BM formation with high therapeutic benefit for patients with HR+ metastatic breast cancer.Significance:Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2− breast cancer, which represents ∼70% of all cases.

  • Open Access

    Supplementary Figures from Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer

    by Rahat Alam, Anna Reva, David G. Edwards, Bree M. Lege, Laura S. Munoz-Arcos, Carolina Reduzzi, Swarnima Singh, Xiaoxin Hao, Yi-Hsuan Wu, Zeru Tian, et al.

    Supplementary Figure 1 Shows the distribution of ERBB2 mutations among metastatic cancer patients, survival outcomes according to metastatic sites (bone vs visceral), and detailed CTC counts from HR+/Her2- MBC patients. Supplementary Figure 2 Shows the therapeutic effect of Tras-ALN on metastasis spread from bone metastasis models of HR+ breast cancer via uCT, live and ex vivo bioluminescence profiling of metastatic organs. Supplementary Figure 3 shows the increased expression of ERBB2 in MSC 3D coculture and anti-ER treatment conditions. Supplementary Figure 4 shows the immune-independent effect of Tras-ALN in blocking metastasis progression. Supplementary Figure 5 shows that direct cell-cell interaction is not required for MSC-induced Her2 expression based on 3D transwell culture conditions. Supplementary 1 of Figure 6 shows genetic modulations of Her2 (ERBB2) in MCF7 and ZR75-1 breast cancer models. Supplementary 2 of Figure 6 shows that genetic alteration of Her2 impacts multiorgan metastasis seeding in HR+ breast cancer models. Supplementary 1 of Figure 7 shows that miRNAs with Her2 targeting potential are associated with overall survival in breast cancer. Supplementary 2 of Figure 7 shows that miR-133a/b abrogates brain metastasis seeding from bone-derived ZR75-1 cells.

  • Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer

    by Rahat Alam, Anna Reva, David G. Edwards, Bree M. Lege, Laura S. Munoz-Arcos, Carolina Reduzzi, Swarnima Singh, Xiaoxin Hao, Yi-Hsuan Wu, Zeru Tian, et al.

    Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort of 137 patients with metastatic breast cancer with initial HR+/HER2− status and use preclinical models of bone metastasis (BM) to validate the role of HER2E CTCs in multiorgan metastases. Although HER2 expression was higher in patients with BM, experimental analyses revealed that HER2E CTCs derived from bone lesions were more dependent on HER2 activity and more susceptible to anti-HER2 therapy. Targeting the bone-mediated HER2 induction reduces CTC detection and abrogates secondary metastasis from the bone. Overall, we elucidate that HER2E CTCs can serve as a noninvasive biomarker for BM formation with high therapeutic benefit for patients with HR+ metastatic breast cancer. Significance: Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2− breast cancer, which represents ∼70% of all cases.


  • Open Access

    Cadherin-dependent adhesion is required for muscle stem cell niche anchorage and maintenance

    by Margaret Hung, Hsiao-Fan Lo, Aviva G. Beckmann, Deniz Demircioglu, Gargi Damle, Dan Hasson, Glenn L. Radice, Robert S. Krauss

    Adhesion between stem cells and their niche provides stable anchorage and signaling cues to sustain properties such as quiescence. Skeletal muscle stem cells (MuSCs) adhere to an adjacent myofiber via cadherin-catenin complexes. Previous studies on N- and M-cadherin in MuSCs revealed that although N-cadherin is required for quiescence, they are collectively dispensable for MuSC niche localization and regenerative activity. Although additional cadherins are expressed at low levels, these findings raise the possibility that cadherins are unnecessary for MuSC anchorage to the niche. To address this question, we conditionally removed from MuSCs β- and γ-catenin, and, separately, αE- and αT-catenin, factors that are essential for cadherin-dependent adhesion. Catenin-deficient MuSCs break quiescence similarly to N-/M-cadherin-deficient MuSCs, but exit the niche and are depleted. Combined in vivo, ex vivo and single cell RNA-sequencing approaches reveal that MuSC attrition occurs via precocious differentiation, re-entry to the niche and fusion to myofibers. These findings indicate that cadherin-catenin-dependent adhesion is required for anchorage of MuSCs to their niche and for preservation of the stem cell compartment. Furthermore, separable cadherin-regulated functions govern niche localization, quiescence and MuSC maintenance.


  • Open Access

    Cadherin-dependent adhesion is required for muscle stem cell niche anchorage and maintenance

    by Margaret Hung, Hsiao-Fan Lo, Aviva G. Beckmann, Deniz Demircioglu, Gargi Damle, Dan Hasson, Glenn L. Radice, Robert S. Krauss

    Adhesion between stem cells and their niche provides stable anchorage and signaling cues to sustain properties such as quiescence. Skeletal muscle stem cells (MuSCs) directly adhere to an adjacent myofiber via cadherin-catenin complexes. Previous studies on N- and M-cadherin function in MuSCs revealed that while N-cadherin is required for quiescence, they are collectively dispensable for MuSC niche localization and regenerative activity. While additional cadherins are expressed at low levels, these findings raise the possibility that cadherins are unnecessary for MuSC anchorage to the niche. To address this question, we conditionally removed from MuSCs β- and γ-catenin and, separately, αE- and αT-catenin, factors essential for cadherin-dependent adhesion. Catenin-deficient MuSCs break quiescence similarly to N-/M-cadherin-deficient MuSCs, but exit the niche, and are depleted. A combination of in vivo, ex vivo, and single cell RNA sequencing approaches reveal that MuSC attrition occurs via a single fate: precocious differentiation, reentry to the niche, and fusion to myofibers. These findings indicate that cadherin-catenin–dependent adhesion is required for anchorage of MuSCs to their niche and preservation of the stem cell compartment. Furthermore, separable, cadherin-regulated functions govern niche localization, quiescence, and stem cell maintenance in MuSCs. SUMMARY STATEMENT: Genetic ablation of cadherin-based adhesion in skeletal muscle stem cells triggers activation, niche exit, precocious differentiation, and subsequent depletion of the stem cell pool.